Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2014

View Archived Issues

Regeneron launches new human genetics initiative via new subsidiary

Portola Pharmaceuticals forms second collaboration with BMS and Pfizer

Regeneron and Bayer enter agreement to develop combination therapy for wet AMD

Crealta Pharmaceuticals completes acquisition of Savient Pharmaceuticals

BioMarin to develop factor VIII gene therapy candidate BMN-270 for hemophilia A

Synthon Biopharmaceuticals prepares for phase I study of SYD-985

Tekmira initiates dosing in phase I trial of anti-Ebola viral therapeutic

Engineered human liver tissues may be an alternate means of generating hepatitis models

NS-018 suppresses CFU-GM colony formation by BMMNCs from high-risk MDS patients

Radius Health reports topline data from phase II abaloparatide study

FDA clears IND for the CHART-2 trial in heart failure

Immunomedics begins phase III trial of yttrium Y 90 clivatuzumab tetraxetan

Synta Pharmaceuticals launches clinical trials evaluating ganetespib in cancer

Bayer reintroduces Diane-35 in France

First patient treated in Neuralstem China stem cell trial in ischemic stroke patients

AG-348 activates mutant PKLR enzymes in patient-derived red cells

AbbVie begins phase III study of veliparib in triple-negative breast cancer

Astellas Pharma reports data from phase III trials of seasonal flu vaccine

IND application filed for GR-MD-02 in metastatic melanoma

Jazz Pharmaceuticals looks towards 2014 with pipeline overview

FDA committee recommends approval of Merck & Co.'s investigational antiplatelet medicine

Italian and Belgian team patents novel anticancer compounds

AstraZeneca identifies BACE1 inhibitors

Positive allosteric modulators of mGlu2 receptors reported in BMS patent

Chinese researchers report discovery of novel DPP IV inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...